A botulinum toxin A (BoNT-A) intravesical injection can improve the symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS).Patients with IC/BPS have different clinical characteristics, urodynamic features, and cystoscopic findings.This study assessed the treatment outcomes of a BoNT-A intravesical injection and aimed to identify the predictive factors of a satisfactory outcome.This retrospective study included IC/BPS patients treated with 100 U BoNT-A.The treatment outcomes were assessed by global response assessment (GRA) at 6 months.
We powell and mahoney bloody mary mix classified patients according to different clinical, urodynamic, and cystoscopic characteristics and evaluated the treatment outcomes and predictive factors.A total of 238 patients were included.Among these patients, 113 (47.5%) had a satisfactory outcome (GRA ≥ 2) and 125 (52.5%) had an unsatisfactory outcome.
Improvements in the IC symptom score, IC problem score, O’Leary−Sant symptom score, and visual analog scale score for pain were significantly greater in patients with a satisfactory outcome than in patients with an unsatisfactory outcome (all p = 0.000).The IC disease duration and maximal bladder capacity (MBC) grandpas best were significantly different between patients with and without a satisfactory outcome.Multivariate analysis revealed that only the MBC was a predictor for a satisfactory outcome.Patients with a MBC of ≥760 mL and glomerulations of 0/1 (58.
7%) or glomerulations of 2/3 (75.0%) frequently had a satisfactory outcome.We found that BoNT-A intravesical injection can effectively improve symptoms among patients with IC/BPS, with a remarkable reduction in bladder pain.A MBC of ≥760 mL is a predictive factor for a satisfactory treatment outcome.